Bora Pharmaceuticals (“Bora”) is an international and fast-growing contract development and manufacturing organization (“CDMO”) specializing in complex oral solid dosage, liquid, and semi-solid pharmaceutical Rx and OTC products for late-phase clinical through commercial manufacturing and packaging. As Bora sought to boost its service offerings in key areas, such as formulation development, sterile ophthalmic, and niche manufacturing technologies, it looked to TWi Pharmaceutical Co. Ltd. (“TWi”), a technology-based company specializing in development and commercialization of niche generic drugs, sharing in its same mission to push the boundaries of product innovation.
To support Bora in its goal to expand on its capabilities as a full-service CDMO, AGG led the U.S. end of this global transaction, conducting time-sensitive corporate and FDA-related due diligence on TWi’s U.S. assets and compliance and providing counsel on U.S. M&A aspects of the deal. AGG Food & Drug practice team leader Alan Minsk and AGG Corporate partner Brian Teras led the team on FDA regulatory and Corporate/M&A matters, respectively. AGG Food & Drug attorneys Bob Durkin and Laura Dona and AGG Corporate attorneys Maggie Scharle and Felix Swierski also assisted in the matter. Additionally, AGG Intellectual Property co-chair and Patent practice leader Kevin Bell provided counsel on patent issues.
Bora is now the largest pharmaceutical group by volume in Taiwan following the TWi acquisition. TWi, which operates in the U.S. via its subsidiary, TWi Pharmaceuticals USA (“TWi USA”), will take advantage of Bora’s existing large-scale production capacity and transfer its commercial manufacturing of its generic and 505(b)(2) new drugs in the U.S. to certain Bora sites.
“The acquisition of TWi Pharmaceuticals marks a huge milestone in Bora’s history . . . [and] will strengthen Bora’s position as a highly diversified global CDMO,” said Bobby Sheng, CEO of Bora. “Our expertise and capacity give us an edge over our competitors as we continue to expand our capabilities.”
To read the full press release, please click here.